COPENHAGEN, Aug 6 (Reuters) - Wegovy-maker Novo Nordisk
reported second-quarter sales up 18% on Wednesday,
below initial analyst expectations, after a major profit warning
and new CEO announcement last week wiped some $95 billion of
value from the company's stock.